Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany.
Bader P, Rossig C, Hutter M, Ayuk FA, Baldus CD, Bücklein VL, Bonig H, Cario G, Einsele H, Holtick U, Koenecke C, Bakhtiar S, Künkele A, Meisel R, Müller F, Müller I, Penack O, Rettinger E, Sauer MG, Schlegel PG, Soerensen J, von Stackelberg A, Strahm B, Hauer J, Feuchtinger T, Jarisch A. Bader P, et al. Among authors: holtick u. Blood Adv. 2023 Jun 13;7(11):2436-2448. doi: 10.1182/bloodadvances.2022008981. Blood Adv. 2023. PMID: 36607834 Free PMC article.
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use.
Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, Kharboutli S, Blumenberg V, Ackermann J, Frölich L, Johnson G, Patel K, Arciola B, Mhaskar R, Wood A, Schmidt C, Albanyan O, Gödel P, Hoster E, Bullinger L, Mackensen A, Locke F, von Bergwelt M, Barba P, Subklewe M, Jain MD. Bücklein V, et al. Among authors: holtick u. Hemasphere. 2023 Jul 11;7(8):e907. doi: 10.1097/HS9.0000000000000907. eCollection 2023 Aug. Hemasphere. 2023. PMID: 37449196 Free PMC article.
Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis.
Derigs P, Bethge WA, Krämer I, Holtick U, von Tresckow B, Ayuk F, Penack O, Vucinic V, von Bonin M, Baldus C, Mougiakakos D, Wulf G, Schnetzke U, Stelljes M, Fante M, Schroers R, Kroeger N, Dreger P; German Lymphoma Alliance and the German Registry for Stem Cell Transplantation. Derigs P, et al. Among authors: holtick u. Transplant Cell Ther. 2023 Dec;29(12):750-756. doi: 10.1016/j.jtct.2023.09.008. Epub 2023 Sep 13. Transplant Cell Ther. 2023. PMID: 37709204
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial.
Schroeder T, Stelljes M, Christopeit M, Esseling E, Scheid C, Mikesch JH, Rautenberg C, Jäger P, Cadeddu RP, Drusenheimer N, Holtick U, Klein S, Trenschel R, Haas R, Germing U, Kröger N, Kobbe G. Schroeder T, et al. Among authors: holtick u. Haematologica. 2023 Nov 1;108(11):3001-3010. doi: 10.3324/haematol.2022.282570. Haematologica. 2023. PMID: 37259567 Free PMC article.
A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation.
Bittrich M, Kriegsmann K, Tietze-Stolley C, Movassaghi K, Grube M, Vucinic V, Wehler D, Burchert A, Schmidt-Hieber M, Rank A, Dürk HA, Metzner B, Kimmich C, Hentrich M, Kunz C, Hartmann F, Khandanpour C, de Wit M, Holtick U, Kiehl M, Stoltefuß A, Kiani A, Naumann R, Scholz CW, Tischler HJ, Görner M, Brand F, Ehmer M, Kröger N. Bittrich M, et al. Among authors: holtick u. Transfus Med Hemother. 2023 Oct 16;50(6):475-490. doi: 10.1159/000531935. eCollection 2023 Dec. Transfus Med Hemother. 2023. PMID: 38089497 Free PMC article.
Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study.
Kriegsmann K, Bittrich M, Sauer S, Tietze-Stolley C, Movassaghi K, Grube M, Vucinic V, Wehler D, Burchert A, Schmidt-Hieber M, Rank A, Dürk HA, Metzner B, Kimmich C, Hentrich M, Kunz C, Hartmann F, Khandanpour C, de Wit M, Holtick U, Kiehl M, Stoltefuß A, Kiani A, Naumann R, Scholz CW, Tischler HJ, Görner M, Brand F, Ehmer M, Kröger N. Kriegsmann K, et al. Among authors: holtick u. Transfus Med Hemother. 2023 Sep 21;50(5):403-416. doi: 10.1159/000531936. eCollection 2023 Oct. Transfus Med Hemother. 2023. PMID: 37899991 Free PMC article.
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.
Weaver AN, Iams WT, Park JC, Mita M, Holtick U, Gordon MS, Rodabaugh KJ, Dhani N, Neupane P, Taylor M, Amanda Duvall E, Jennings J, Miselis NR, Loughhead S, Warren MS, Bernstein H, Klussmann JP, Baranda J, Jimeno A. Weaver AN, et al. Among authors: holtick u. Mol Carcinog. 2024 May 2. doi: 10.1002/mc.23738. Online ahead of print. Mol Carcinog. 2024. PMID: 38695604
Post-transplant-cyclophosphamide and short-term Everolimus as graft-versus-host-prophylaxis in patients with relapsed/refractory lymphoma and myeloma-Final results of the phase II OCTET-EVER trial.
Richardson T, Scheid C, Herling M, Frenzel LP, Herling C, Aguilar MRC, Theurich S, Hallek M, Holtick U. Richardson T, et al. Among authors: holtick u. Eur J Haematol. 2024 Apr 14. doi: 10.1111/ejh.14210. Online ahead of print. Eur J Haematol. 2024. PMID: 38616351
107 results